Diltiazem: A Comprehensive Overview Of A Calcium Channel Blocker

Diltiazem is a widely prescribed cardiovascular medication belonging to the class of drugs known as calcium channel blockers (CCBs), specifically the benzothiazepine subclass. First approved for medical use in the 1970s, it has since become a cornerstone in the management of various cardiac conditions due to its efficacy and relatively favorable safety profile. Its primary mechanism of action, therapeutic applications, pharmacokinetics, side effects, and important clinical considerations form the basis of this report.



Mechanism of Action
Diltiazem exerts its therapeutic effects by selectively inhibiting the influx of calcium ions through L-type calcium channels in cardiac and vascular smooth muscle cells. In the heart, this inhibition results in a decrease in sinoatrial (SA) node automaticity and atrioventricular (AV) node conduction velocity, leading to a reduction in heart rate (negative chronotropy) and a modest decrease in myocardial contractility (negative inotropy). In the peripheral and coronary arteries, the inhibition of calcium influx causes vasodilation, reducing systemic vascular resistance and blood pressure, while simultaneously increasing blood flow and oxygen supply to the heart muscle. This dual action on the heart and vasculature underpins its utility in treating both arrhythmias and hypertension/angina.



Therapeutic Indications
Diltiazem is approved for several key cardiovascular conditions:

Hypertension: As an antihypertensive agent, diltiazem lowers blood pressure primarily through arterial vasodilation, reducing the workload on the heart.
Chronic Stable Angina: It relieves and prevents angina pectoris by dilating coronary arteries, improving myocardial oxygen supply, and reducing heart rate and contractility, thereby decreasing oxygen demand.
Vasospastic (Prinzmetal's) Angina: It is particularly effective in preventing coronary artery spasm.
Supraventricular Arrhythmias: Diltiazem is used to control ventricular rate in atrial fibrillation and atrial flutter and to terminate paroxysmal supraventricular tachycardia (PSVT) due to its potent effects on AV node conduction. An intravenous formulation is available for acute rate control.

Pharmacokinetics and Dosage Forms

Diltiazem is available in multiple oral formulations and as an intravenous injection. Oral forms include immediate-release capsules, extended-release (ER) capsules, and sustained-release tablets, allowing for once- or twice-daily dosing in chronic management. It undergoes extensive first-pass metabolism in the liver primarily via the cytochrome P450 enzyme CYP3A4, resulting in a bioavailability of approximately 40-50%. Its active metabolite, desacetyldiltiazem, possesses about 25-50% of the parent drug's activity. The elimination half-life is about 3-4.5 hours for the immediate-release form but is prolonged in extended-release formulations. Excretion is primarily via the kidneys and bile. Dosage must be individualized and often requires adjustment in patients with hepatic impairment.



Adverse Effects and Contraindications
Diltiazem is generally well-tolerated, but adverse effects can occur, often related to its vasodilatory and cardiac effects. Common side effects include headache, dizziness, flushing, peripheral edema, and fatigue. Bradycardia and AV conduction abnormalities (e.g., first- or second-degree heart block) are more serious cardiac effects. Constipation is a notable side effect due to its effect on gastrointestinal smooth muscle.
Contraindications include patients with sick sinus syndrome (except with a functioning pacemaker), second- or third-degree AV block (without a pacemaker), severe hypotension (systolic

Drug Interactions and Clinical Considerations
Diltiazem is a moderate inhibitor of CYP3A4 and a substrate for P-glycoprotein, leading to numerous potential drug interactions. Coadministration with other CYP3A4 substrates can increase their plasma concentrations, raising the risk of toxicity. Key interactions include:
Beta-blockers: Concurrent use can potentiate bradycardia and AV block; monitoring is essential.
Digoxin: Diltiazem can increase serum digoxin levels by 20-40%, necessitating monitoring and possible dose reduction.
Statins (e.g., simvastatin, lovastatin, atorvastatin)[https://corazondecarcar.es/ Biltricide €0.71 ���� : Praziquantel 600mg sin receta] Increased risk of myopathy/rhabdomyolysis; dose limitations are recommended.
Cyclosporine, Sirolimus, Tacrolimus: Diltiazem can significantly increase levels of these immunosuppressants.

Anesthetics: Additive hypotensive effects.
Patients should be advised to avoid grapefruit juice, which inhibits CYP3A4 and can markedly increase diltiazem bioavailability.


Special Populations and Role in Therapy
In elderly patients, lower starting doses are recommended due to age-related changes in pharmacokinetics and increased sensitivity. Its use in pregnancy (Category C) and lactation requires careful risk-benefit assessment. In renal impairment, standard doses are often acceptable, but caution is advised. Diltiazem holds a significant place in therapy, often preferred in patients with concomitant angina or supraventricular arrhythmias, or as an alternative for those who cannot tolerate beta-blockers. Its vasoselectivity is intermediate between the dihydropyridines (e.g., amlodipine) and verapamil, offering a balanced profile.



Conclusion
Diltiazem remains a fundamental agent in cardiology, offering versatile treatment for hypertension, angina, and certain arrhythmias through its modulation of calcium channels. Understanding its pharmacokinetics, potential for drug interactions, and contraindications is crucial for safe and effective prescribing. As with all cardiovascular medications, therapy must be tailored to the individual patient, considering comorbidities and concomitant medications to optimize outcomes and minimize risks.